ZA201004045B - Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods - Google Patents

Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods

Info

Publication number
ZA201004045B
ZA201004045B ZA2010/04045A ZA201004045A ZA201004045B ZA 201004045 B ZA201004045 B ZA 201004045B ZA 2010/04045 A ZA2010/04045 A ZA 2010/04045A ZA 201004045 A ZA201004045 A ZA 201004045A ZA 201004045 B ZA201004045 B ZA 201004045B
Authority
ZA
South Africa
Prior art keywords
polypeptides
inflammatory
enhanced anti
cytotoxic properties
decreased cytotoxic
Prior art date
Application number
ZA2010/04045A
Other languages
English (en)
Inventor
Falk Nimmerjahn
Yoshikatsu Kaneko
Jeffrey Ravetch
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Publication of ZA201004045B publication Critical patent/ZA201004045B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2010/04045A 2007-12-14 2010-06-07 Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods ZA201004045B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/957,015 US20080206246A1 (en) 2006-04-05 2007-12-14 Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
PCT/US2008/086622 WO2009079382A1 (en) 2007-12-14 2008-12-12 Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods

Publications (1)

Publication Number Publication Date
ZA201004045B true ZA201004045B (en) 2011-03-30

Family

ID=40796321

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/04045A ZA201004045B (en) 2007-12-14 2010-06-07 Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods

Country Status (11)

Country Link
US (1) US20080206246A1 (enExample)
EP (1) EP2227255A4 (enExample)
JP (1) JP2011506476A (enExample)
CN (1) CN101896202A (enExample)
AU (1) AU2008338550A1 (enExample)
CA (1) CA2707304A1 (enExample)
EA (1) EA201070739A1 (enExample)
IL (1) IL206029A0 (enExample)
MX (1) MX2010006537A (enExample)
WO (1) WO2009079382A1 (enExample)
ZA (1) ZA201004045B (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470318B2 (en) * 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP3456351A1 (en) * 2006-04-05 2019-03-20 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20110150867A1 (en) * 2007-12-14 2011-06-23 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP2279410B1 (en) * 2008-04-22 2015-11-11 The Rockefeller University Methods of identifying anti-inflammatory compounds
EP2233499A1 (en) * 2009-03-26 2010-09-29 CSL Behring AG Antibody composition with altered Fab sialylation
EP2427497B1 (fr) 2009-05-07 2016-12-07 Stallergenes Utilisation d'immunoglobulines igg1 et/ou de ligands du récepteur cd32 pour le traitement de maladies et manifestations inflammatoires par voie mucosale
MX2012005527A (es) 2009-11-13 2012-08-08 Grifols Therapeutics Inc Preparaciones que contienen el factor de von willebrand (fvw) procedimientos, kits y aplicaciones relacionados con las mismas.
US20130058917A1 (en) * 2010-05-07 2013-03-07 Fabian Käsermann Antibody composition obtained by fractionation of plasma immunoglobulins affinity chromatography on a sambucus nigra affinity column
WO2011149999A2 (en) * 2010-05-27 2011-12-01 Merck Sharp & Dohme Corp. Method for preparing antibodies having improved properties
AR085302A1 (es) * 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
CN103582650A (zh) * 2011-05-25 2014-02-12 默沙东公司 用于制备具有改善性质的含Fc多肽的方法
IN2014CN03072A (enExample) * 2011-10-31 2015-07-31 Merck Sharp & Dohme
WO2013074598A1 (en) * 2011-11-18 2013-05-23 Merck Sharp & Dohme Corp. Fc CONTAINING POLYPEPTIDES HAVING INCREASED ANTI-INFLAMMATORY PROPERTIES AND INCREASED FcRN BINDING
CN104010659A (zh) 2011-12-19 2014-08-27 洛克菲勒大学 非唾液酸化的抗炎多肽
US12384848B2 (en) * 2011-12-19 2025-08-12 The Rockefeller University Anti-inflammatory polypeptides
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CN110894231A (zh) 2012-10-17 2020-03-20 康诺贝林伦瑙有限公司 免疫调节蛋白
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
ES2708565T3 (es) 2013-03-15 2019-04-10 Atyr Pharma Inc Conjugados de Fc-histidil-ARNt sintetasa
WO2014149067A1 (en) 2013-03-15 2014-09-25 Momenta Pharmaceuticals, Inc. Methods related to ctla4-fc fusion proteins
US10464996B2 (en) 2013-05-13 2019-11-05 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US20160257754A1 (en) 2013-10-16 2016-09-08 Momenta Pharmaceuticals Inc. Sialylated glycoproteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015106123A1 (en) * 2014-01-09 2015-07-16 The Johns Hopkins University Use of high flux scfa-derivatized monosaccharides in recombinant glycoprotein production
DK3221363T3 (da) 2014-11-21 2020-08-10 Bristol Myers Squibb Co Antistoffer mod cd73 og anvendelser deraf
HRP20201756T8 (hr) 2014-11-21 2021-08-20 Bristol-Myers Squibb Company Antitijela koja sadrže modificirane regije teškog lanca
SG10202006538TA (en) 2014-12-23 2020-08-28 Bristol Myers Squibb Co Antibodies to tigit
LT3303396T (lt) 2015-05-29 2023-01-10 Bristol-Myers Squibb Company Antikūnai prieš ox40 ir jų panaudojimo būdai
MX2017016502A (es) 2015-06-29 2018-03-12 Univ Rockefeller Anticuerpos contra cd40 con actividad agonista mejorada.
FR3038517B1 (fr) * 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
KR20180118725A (ko) 2016-03-04 2018-10-31 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
CA3016534A1 (en) 2016-03-04 2017-09-08 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
EP3612215B1 (en) 2017-04-20 2024-08-28 aTyr Pharma, Inc. Compositions for treating lung inflammation
IL270596B1 (en) 2017-05-25 2025-09-01 Bristol Myers Squibb Co Antibodies comprising modified heavy constant region for use in treating cancer
CA3085472A1 (en) 2017-12-19 2019-06-27 The Rockefeller University Human igg fc domain variants with improved effector function
KR102813744B1 (ko) 2017-12-27 2025-05-28 브리스톨-마이어스 스큅 컴퍼니 항-cd40 항체 및 그의 용도
TW202033555A (zh) 2018-11-16 2020-09-16 美商必治妥美雅史谷比公司 抗nkg2a抗體及其用途
KR20210096167A (ko) 2018-11-28 2021-08-04 브리스톨-마이어스 스큅 컴퍼니 변형된 중쇄 불변 영역을 포함하는 항체
KR102549282B1 (ko) * 2019-11-18 2023-06-30 건국대학교 산학협력단 시알산화된 면역글로불린을 유효성분으로 포함하는 염증성 질환의 치료용 조성물
EP4114547A4 (en) * 2020-03-05 2024-03-27 Momenta Pharmaceuticals, Inc. METHOD FOR PRODUCING HYPERSIALYLATED IMMUNOGLOBULIN
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
US20240425606A1 (en) 2021-08-30 2024-12-26 Lassen Therapeutics 1, Inc. Anti-il-11ra antibodies
EP4446345A4 (en) * 2021-12-09 2025-08-20 Shanghai Bao Pharmaceuticals Co Ltd FC POLYPEPTIDE WITH MODIFIED GLYCOSYLATION MODIFICATION
CN120787238A (zh) 2023-01-06 2025-10-14 拉森医疗公司 用于治疗甲状腺眼病的抗IL-11Rα抗体
TW202430560A (zh) 2023-01-06 2024-08-01 美商拉森醫療公司 抗ｉｌ－１８ｂｐ抗體
CN120530131A (zh) 2023-01-06 2025-08-22 拉森医疗公司 抗il-18bp抗体

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2556219B1 (fr) * 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
HUT64476A (en) * 1990-11-23 1994-01-28 Gen Hospital Corp Process for inhibiting interacton between proteins and carbohydrate causing cell-adhesion
ATE289354T1 (de) * 1999-04-15 2005-03-15 Crucell Holland Bv Verwendung von adenovirus e1 protein sequenzen kodierenden, zur herstellung von rekombinanten proteinen in menschlichen zellen.
DE19927835A1 (de) * 1999-06-18 2000-12-21 Clariant Gmbh Verwendung von verbesserten Cyanpigmenten in elektrophotographischen Tonern und Entwicklern, Pulverlacken und Ink-Jet-Tinten
US7064191B2 (en) * 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US7427469B2 (en) * 2002-11-05 2008-09-23 Institut Pasteur Method of treating cytomegalovirus with DC-SIGN blockers
US20070048740A1 (en) * 2003-02-14 2007-03-01 Research Association For Biotechnology Full-length cDNA
US7155641B2 (en) * 2003-05-15 2006-12-26 Microsoft Corporation System and method for monitoring the performance of a server
ME01775B (me) * 2003-11-05 2011-02-28 Glycart Biotechnology Ag Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
EP1699487A4 (en) * 2003-12-15 2009-07-08 Alexion Pharma Inc NEW ANTI-DC-SIGN ANTIBODIES
AU2006283560B2 (en) * 2005-08-19 2011-12-08 Centocor, Inc. Proteolysis resistant antibody preparations
CA2627981A1 (en) * 2005-11-07 2007-05-18 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
WO2008057634A2 (en) * 2006-10-26 2008-05-15 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP3456351A1 (en) * 2006-04-05 2019-03-20 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
JP2009087163A (ja) * 2007-10-01 2009-04-23 Brother Ind Ltd ジョブ実行装置及びジョブ実行方法

Also Published As

Publication number Publication date
AU2008338550A1 (en) 2009-06-25
US20080206246A1 (en) 2008-08-28
MX2010006537A (es) 2010-12-06
EP2227255A1 (en) 2010-09-15
JP2011506476A (ja) 2011-03-03
CN101896202A (zh) 2010-11-24
EP2227255A4 (en) 2011-08-10
IL206029A0 (en) 2010-11-30
WO2009079382A1 (en) 2009-06-25
CA2707304A1 (en) 2009-06-25
EA201070739A1 (ru) 2010-12-30

Similar Documents

Publication Publication Date Title
ZA201004045B (en) Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
IL194526A0 (en) Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
IL237314A0 (en) Modified insulin polypeptides and their uses
GB0717507D0 (en) Composite materials and their use
EP2220270A4 (en) METALLIC STRUCTURES WITH VARIABLE PROPERTIES
ZA201201218B (en) 3-polylysine conjugates and the use thereof
IL201791A0 (en) Modified interferon beta polypeptides and their uses
IL205571A0 (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin
IL218776A0 (en) Modified factor vii polypeptides and uses thereof
GB0702020D0 (en) Peptides and their use
EP2185692A4 (en) HCO32 AND HCO27 AND RELATED EXAMPLES
GB0720579D0 (en) Functionalised materials and uses thereof
IL207096A0 (en) Modified leptin polypeptides and their uses
EP2370472A4 (en) LEPTIN AND LEPTIN ANALOGUE CONJUGATES AND ITS USES
GB0708376D0 (en) Novel polypeptides and uses thereof
EP2205677A4 (en) NETWORKABLE FLUOROLPOLYMER COMPOSITION AND USES THEREOF
HUE038552T2 (hu) Bevonó anyag szilárd gyógyszerhez és a kapott szilárd gyógyszer
SI2068909T1 (sl) Modificirani fgf-21 polipeptidi in njihova uporaba
GB0702021D0 (en) Peptides and their use
IL197920A0 (en) Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
GB0702022D0 (en) Peptides and their use
GB0717376D0 (en) Composition and manufacture thereof
ZA200907412B (en) Improvements in the production of ferro-alloys
IL206104A0 (en) Aminothiazoles and their uses
HK1148933A (en) Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods